Financhill
Sell
25

VTRS Quote, Financials, Valuation and Earnings

Last price:
$9.5200
Seasonality move :
2.82%
Day range:
$9.2700 - $9.6900
52-week range:
$8.7701 - $13.5500
Dividend yield:
5.13%
P/E ratio:
--
P/S ratio:
0.76x
P/B ratio:
0.60x
Volume:
27.6M
Avg. volume:
11.9M
1-year change:
-25.73%
Market cap:
$11.2B
Revenue:
$14.7B
EPS (TTM):
-$0.53

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VTRS
Viatris
$3.6B $0.57 -8.04% 462.31% $12.5125
AMPH
Amphastar Pharmaceuticals
$188.8M $0.94 1.53% -16.05% $39.80
ANIP
ANI Pharmaceuticals
$175.4M $1.44 23.67% 39.33% $80.83
BSX
Boston Scientific
$4.4B $0.66 18.49% 103.21% $115.01
IOVA
Iovance Biotherapeutics
$72.2M -$0.27 11658.43% -42.51% $19.62
PODD
Insulet
$582M $1.02 23.07% 6.17% $312.88
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VTRS
Viatris
$9.3500 $12.5125 $11.2B -- $0.12 5.13% 0.76x
AMPH
Amphastar Pharmaceuticals
$27.52 $39.80 $1.3B 8.99x $0.00 0% 1.96x
ANIP
ANI Pharmaceuticals
$58.47 $80.83 $1.3B 55.43x $0.00 0% 1.85x
BSX
Boston Scientific
$104.87 $115.01 $154.8B 83.90x $0.00 0% 9.31x
IOVA
Iovance Biotherapeutics
$4.03 $19.62 $1.3B -- $0.00 0% 7.11x
PODD
Insulet
$272.64 $312.88 $19.1B 47.09x $0.00 0% 9.72x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VTRS
Viatris
42.97% 0.995 94.47% 0.80x
AMPH
Amphastar Pharmaceuticals
45.11% 0.843 34.04% 2.07x
ANIP
ANI Pharmaceuticals
59.29% 0.260 52.37% 1.93x
BSX
Boston Scientific
32.79% 0.683 8.05% 0.46x
IOVA
Iovance Biotherapeutics
0.14% 0.652 0.04% 3.21x
PODD
Insulet
53.47% 1.510 7.6% 2.50x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VTRS
Viatris
$1.2B -$38.2M -1.75% -3.22% -11.52% $329.3M
AMPH
Amphastar Pharmaceuticals
$86.6M $45.1M 12.36% 22.89% 27.01% $16.6M
ANIP
ANI Pharmaceuticals
$110.3M $1.3M -2.11% -4.07% -4.07% $13.4M
BSX
Boston Scientific
$3.1B $790M 5.97% 8.96% 14.58% $1.2B
IOVA
Iovance Biotherapeutics
$28.2M -$86.6M -52.84% -52.91% -117.48% -$77.5M
PODD
Insulet
$430.9M $109.3M 17.64% 43.11% 20.08% $91.7M

Viatris vs. Competitors

  • Which has Higher Returns VTRS or AMPH?

    Amphastar Pharmaceuticals has a net margin of -14.64% compared to Viatris's net margin of 20.35%. Viatris's return on equity of -3.22% beat Amphastar Pharmaceuticals's return on equity of 22.89%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTRS
    Viatris
    34.44% -$0.43 $32.7B
    AMPH
    Amphastar Pharmaceuticals
    46.45% $0.74 $1.3B
  • What do Analysts Say About VTRS or AMPH?

    Viatris has a consensus price target of $12.5125, signalling upside risk potential of 33.82%. On the other hand Amphastar Pharmaceuticals has an analysts' consensus of $39.80 which suggests that it could grow by 44.62%. Given that Amphastar Pharmaceuticals has higher upside potential than Viatris, analysts believe Amphastar Pharmaceuticals is more attractive than Viatris.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTRS
    Viatris
    2 5 0
    AMPH
    Amphastar Pharmaceuticals
    2 3 0
  • Is VTRS or AMPH More Risky?

    Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison Amphastar Pharmaceuticals has a beta of 0.768, suggesting its less volatile than the S&P 500 by 23.238%.

  • Which is a Better Dividend Stock VTRS or AMPH?

    Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.13%. Amphastar Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Amphastar Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTRS or AMPH?

    Viatris quarterly revenues are $3.5B, which are larger than Amphastar Pharmaceuticals quarterly revenues of $186.5M. Viatris's net income of -$516.5M is lower than Amphastar Pharmaceuticals's net income of $38M. Notably, Viatris's price-to-earnings ratio is -- while Amphastar Pharmaceuticals's PE ratio is 8.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 1.96x for Amphastar Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTRS
    Viatris
    0.76x -- $3.5B -$516.5M
    AMPH
    Amphastar Pharmaceuticals
    1.96x 8.99x $186.5M $38M
  • Which has Higher Returns VTRS or ANIP?

    ANI Pharmaceuticals has a net margin of -14.64% compared to Viatris's net margin of -5.39%. Viatris's return on equity of -3.22% beat ANI Pharmaceuticals's return on equity of -4.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTRS
    Viatris
    34.44% -$0.43 $32.7B
    ANIP
    ANI Pharmaceuticals
    57.88% -$0.55 $1.1B
  • What do Analysts Say About VTRS or ANIP?

    Viatris has a consensus price target of $12.5125, signalling upside risk potential of 33.82%. On the other hand ANI Pharmaceuticals has an analysts' consensus of $80.83 which suggests that it could grow by 38.25%. Given that ANI Pharmaceuticals has higher upside potential than Viatris, analysts believe ANI Pharmaceuticals is more attractive than Viatris.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTRS
    Viatris
    2 5 0
    ANIP
    ANI Pharmaceuticals
    2 1 0
  • Is VTRS or ANIP More Risky?

    Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison ANI Pharmaceuticals has a beta of 0.625, suggesting its less volatile than the S&P 500 by 37.453%.

  • Which is a Better Dividend Stock VTRS or ANIP?

    Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.13%. ANI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. ANI Pharmaceuticals pays out -8.77% of its earnings as a dividend.

  • Which has Better Financial Ratios VTRS or ANIP?

    Viatris quarterly revenues are $3.5B, which are larger than ANI Pharmaceuticals quarterly revenues of $190.6M. Viatris's net income of -$516.5M is lower than ANI Pharmaceuticals's net income of -$10.3M. Notably, Viatris's price-to-earnings ratio is -- while ANI Pharmaceuticals's PE ratio is 55.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 1.85x for ANI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTRS
    Viatris
    0.76x -- $3.5B -$516.5M
    ANIP
    ANI Pharmaceuticals
    1.85x 55.43x $190.6M -$10.3M
  • Which has Higher Returns VTRS or BSX?

    Boston Scientific has a net margin of -14.64% compared to Viatris's net margin of 12.41%. Viatris's return on equity of -3.22% beat Boston Scientific's return on equity of 8.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTRS
    Viatris
    34.44% -$0.43 $32.7B
    BSX
    Boston Scientific
    67.86% $0.38 $32.6B
  • What do Analysts Say About VTRS or BSX?

    Viatris has a consensus price target of $12.5125, signalling upside risk potential of 33.82%. On the other hand Boston Scientific has an analysts' consensus of $115.01 which suggests that it could grow by 9.67%. Given that Viatris has higher upside potential than Boston Scientific, analysts believe Viatris is more attractive than Boston Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTRS
    Viatris
    2 5 0
    BSX
    Boston Scientific
    23 4 0
  • Is VTRS or BSX More Risky?

    Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

  • Which is a Better Dividend Stock VTRS or BSX?

    Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.13%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTRS or BSX?

    Viatris quarterly revenues are $3.5B, which are smaller than Boston Scientific quarterly revenues of $4.6B. Viatris's net income of -$516.5M is lower than Boston Scientific's net income of $566M. Notably, Viatris's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 83.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 9.31x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTRS
    Viatris
    0.76x -- $3.5B -$516.5M
    BSX
    Boston Scientific
    9.31x 83.90x $4.6B $566M
  • Which has Higher Returns VTRS or IOVA?

    Iovance Biotherapeutics has a net margin of -14.64% compared to Viatris's net margin of -106.6%. Viatris's return on equity of -3.22% beat Iovance Biotherapeutics's return on equity of -52.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTRS
    Viatris
    34.44% -$0.43 $32.7B
    IOVA
    Iovance Biotherapeutics
    38.2% -$0.26 $711.4M
  • What do Analysts Say About VTRS or IOVA?

    Viatris has a consensus price target of $12.5125, signalling upside risk potential of 33.82%. On the other hand Iovance Biotherapeutics has an analysts' consensus of $19.62 which suggests that it could grow by 387.34%. Given that Iovance Biotherapeutics has higher upside potential than Viatris, analysts believe Iovance Biotherapeutics is more attractive than Viatris.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTRS
    Viatris
    2 5 0
    IOVA
    Iovance Biotherapeutics
    8 2 0
  • Is VTRS or IOVA More Risky?

    Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison Iovance Biotherapeutics has a beta of 0.931, suggesting its less volatile than the S&P 500 by 6.856%.

  • Which is a Better Dividend Stock VTRS or IOVA?

    Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.13%. Iovance Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Iovance Biotherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTRS or IOVA?

    Viatris quarterly revenues are $3.5B, which are larger than Iovance Biotherapeutics quarterly revenues of $73.7M. Viatris's net income of -$516.5M is lower than Iovance Biotherapeutics's net income of -$78.6M. Notably, Viatris's price-to-earnings ratio is -- while Iovance Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 7.11x for Iovance Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTRS
    Viatris
    0.76x -- $3.5B -$516.5M
    IOVA
    Iovance Biotherapeutics
    7.11x -- $73.7M -$78.6M
  • Which has Higher Returns VTRS or PODD?

    Insulet has a net margin of -14.64% compared to Viatris's net margin of 16.85%. Viatris's return on equity of -3.22% beat Insulet's return on equity of 43.11%.

    Company Gross Margin Earnings Per Share Invested Capital
    VTRS
    Viatris
    34.44% -$0.43 $32.7B
    PODD
    Insulet
    72.12% $1.39 $2.6B
  • What do Analysts Say About VTRS or PODD?

    Viatris has a consensus price target of $12.5125, signalling upside risk potential of 33.82%. On the other hand Insulet has an analysts' consensus of $312.88 which suggests that it could grow by 14.76%. Given that Viatris has higher upside potential than Insulet, analysts believe Viatris is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    VTRS
    Viatris
    2 5 0
    PODD
    Insulet
    14 4 0
  • Is VTRS or PODD More Risky?

    Viatris has a beta of 0.922, which suggesting that the stock is 7.819% less volatile than S&P 500. In comparison Insulet has a beta of 1.285, suggesting its more volatile than the S&P 500 by 28.544%.

  • Which is a Better Dividend Stock VTRS or PODD?

    Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.13%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VTRS or PODD?

    Viatris quarterly revenues are $3.5B, which are larger than Insulet quarterly revenues of $597.5M. Viatris's net income of -$516.5M is lower than Insulet's net income of $100.7M. Notably, Viatris's price-to-earnings ratio is -- while Insulet's PE ratio is 47.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.76x versus 9.72x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VTRS
    Viatris
    0.76x -- $3.5B -$516.5M
    PODD
    Insulet
    9.72x 47.09x $597.5M $100.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is GEO Stock a Buy, Sell or Hold?
Is GEO Stock a Buy, Sell or Hold?

The GEO Group (NYSE:GEO) is a private prison and mental…

Why Did Sunrise Communications Stock Drop?
Why Did Sunrise Communications Stock Drop?

Sunrise Communications (NASDAQ:SNRE) is a Swiss mobile telephone, TV and…

Will Rocket Lab Stock Recover?
Will Rocket Lab Stock Recover?

Shares of space vehicle launch company Rocket Lab (NASDAQ:RKLB) have…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Sell
46
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
83
THLLY alert for Mar 4

Thales [THLLY] is up 5% over the past day.

Buy
89
BAESY alert for Mar 4

BAE Systems PLC [BAESY] is down 1.75% over the past day.

Sell
33
GDS alert for Mar 4

GDS Holdings [GDS] is up 11.47% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock